Biotechnology company Calico, which is owned by Google, said it will license and develop potential drugs for neurodegenerative disorders caused by the aging and death of nerve cells.
Researchers from UT Southwestern Medical Center recently published a paper about P7C3 compounds, which have been shown to help in various animal models of age-related neurocognitive impairment, Parkinson’s disease, amyotrophic lateral sclerosis, and depression.
The new study showed that these compounds activate a cellular enzyme involved in energy metabolism crucial to the functioning and survival of cells. Another recently published study showed that P7C3 compounds protected rodents’ brains against dysfunction when administered after traumatic injuries.
2M Companies in Dallas previously held the license for P7C3 compounds. Under a new agreement, Calico will take responsibility for developing and commercializing the compounds generated by the research program. Calico, based in South San Francisco, will fund research labs in the Dallas area, among other locations.
As part of the agreement, Calico will give 2M an unspecified up-front fee, milestones, and royalty payments in exchange for an exclusive worldwide license to the P7C3 program as well as other compounds involved in energy metabolism.
Dr. Hal Barron, president of research and development at Calico, said of the collaboration, “We look forward to working with the world-leading scientists who discovered the P73C class of molecules to learn whether the remarkable biological effects can be translated to the treatment of human disease.”
Calico’s plans to tackle aging are finally taking shape thanks to an agreement with a Texas-based research program. The Google-backed biotechnology company announced it will license and develop potential drugs for neurodegenerative disorders caused by the aging and death of nerve cells after a study showed that P7C3 compounds activate a cellular enzyme involved in energy metabolism that is crucial to the functioning and survival of cells.